亚太药代动力学服务市场预测至 2031 年 - 区域分析 - 按药物类型（小分子、大分子和疫苗）、服务类型（临床前 ADME 和人体研究、PK/PD 分析和报告、剂量模拟、风险分析等）、治疗应用（肿瘤学、传染病、神经系统疾病、自身免疫性疾病、妇科疾病、心血管疾病、呼吸系统疾病等）和最终用户（制药和生物技术公司、合同研究组织等）

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2031

Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)

No. of Pages: 95    |    Report Code: BMIRE00030886    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Pharmacokinetics Services Market
Free Sample Buy Now
2023 年亚太药代动力学服务市场价值为 1.9144 亿美元，预计到 2031 年将达到 3.5658 亿美元；预计 2023 年至 2031 年的复合年增长率为 8.1%。

越来越多地采用体内和体外模型来了解药代动力学的变化，推动亚太药代动力学服务市场发展

收集和处理药品制造过程中产生的大量药代动力学数据是一项昂贵、繁琐且耗时的任务。这些任务的劳动和成本密集性质凸显了对药代动力学模拟模型和体外-体内药代动力学相关模型 (IVIVC) 等模型的需求，以预测药代动力学参数。药代动力学模拟模型是一种使用计算和数学模型解释特定条件下生活环境中药物动力学的工具。此外，IVIVC 模型是药物发现过程的基本组成部分。在药物开发的早期阶段分析 PK/PD 预测对于先导优化策略和进一步降低流失率是必要的。在开发新的体外和体内策略以改善和表征药代动力学特性方面取得了重大进展。IVIVC 模型被提议作为一种经济有效的替代方案来评估分析药物生物利用度及其应用的生物制药特性。因此，预计此类体内和体外模型将在不久的将来为亚太药代动力学服务市场提供丰厚的机会。

亚太药代动力学服务市场概览

中国亚太药代动力学服务市场的增长主要归因于成熟的制药市场、制药和生物制药公司不断增加的研发支出、由于运营成本降低而增加的临床试验数量以及有利的监管政策。根据 2023 年发布的 EFPIA 报告，中国制药公司的研发支出从 2020 年的 108.1423 亿美元增长到 2021 年的 129.8923 亿美元。中国拥有世界第二大医药市场。该国人口过剩，再加上各种非传染性和传染性疾病病例的增加，刺激了对新药物分子的需求，这使得中国成为亚太地区的主要市场。

亚太药代动力学服务市场收入和预测到 2031 年（百万美元）

亚太药代动力学服务市场细分

亚太药代动力学服务市场分为药物类型、服务类型、治疗应用、最终用户和国家。

根据药物类型，亚太药代动力学服务市场分为小分子、大分子和疫苗。小分子细分市场在 2023 年占据最大市场份额。

就服务类型而言，亚太药代动力学服务市场分为临床前 ADME 和人体研究、PK/PD 分析和报告、剂量模拟、风险分析等。临床前 ADME 和人体研究细分市场在 2023 年占据最大市场份额。

按治疗应用，亚太药代动力学服务市场细分为肿瘤学、传染病、神经系统疾病、自身免疫性疾病、妇科疾病、心血管疾病、呼吸系统疾病等。肿瘤学细分市场在 2023 年占据最大市场份额。

按最终用户，亚太药代动力学服务市场细分为制药和生物技术公司、合同研究组织等。合同研究组织部门在 2023 年占据了最大的市场份额。

按国家/地区划分，亚太药代动力学服务市场分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。日本在 2023 年占据了亚太药代动力学服务市场份额的主导地位。

Allucent；Certara Inc.；Charles River Laboratories International Inc；Eurofins Scientific SE；PACIFIC BIOLABS；Parexel International Corp；SGS SA；上海美迪西公司；和赛默飞世尔科技公司是亚太药代动力学服务市场的一些领先公司。

Asia Pacific Pharmacokinetics Services Strategic Insights

Strategic insights for Asia Pacific Pharmacokinetics Services involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-pharmacokinetics-services-market-strategic-framework.webp
Get more information on this report

Asia Pacific Pharmacokinetics Services Report Scope

Report Attribute Details
Market size in 2023 US$ 191.44 Million
Market Size by 2031 US$ 356.58 Million
Global CAGR (2023 - 2031) 8.1%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By 药物类型
  • 小分子
  • 大分子
  • 疫苗
By 服务类型
  • 临床前 ADME 和人体研究
  • PK/PD 分析和报告
  • 剂量模拟
  • 风险分析
By 最终用户
  • 制药和生物技术公司
  • 合同研究组织
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Allucent
  • Certara Inc.
  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • PACIFIC BIOLABS
  • Parexel International Corp
  • SGS SA
  • Shanghai Medicilon Inc.
  • Thermo Fisher Scientific Inc.
    		•
    Get more information on this report

    Asia Pacific Pharmacokinetics Services Regional Insights

    The regional scope of Asia Pacific Pharmacokinetics Services refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-pharmacokinetics-services-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - Asia Pacific Pharmacokinetics Services Market

    1. Allucent
    2. Certara Inc.
    3. Charles River Laboratories International Inc
    4. Eurofins Scientific SE
    5. PACIFIC BIOLABS
    6. Parexel International Corp
    7. SGS SA
    8. Shanghai Medicilon Inc.
    9. Thermo Fisher Scientific Inc.
    Frequently Asked Questions
    How big is the Asia Pacific Pharmacokinetics Services Market?

    The Asia Pacific Pharmacokinetics Services Market is valued at US$ 191.44 Million in 2023, it is projected to reach US$ 356.58 Million by 2031.

    What is the CAGR for Asia Pacific Pharmacokinetics Services Market by (2023 - 2031)?

    As per our report Asia Pacific Pharmacokinetics Services Market, the market size is valued at US$ 191.44 Million in 2023, projecting it to reach US$ 356.58 Million by 2031. This translates to a CAGR of approximately 8.1% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Pharmacokinetics Services Market report typically cover these key segments-

  • 药物类型 (小分子, 大分子, 疫苗)
  • 服务类型 (临床前 ADME 和人体研究, PK/PD 分析和报告, 剂量模拟, 风险分析)
  • 最终用户 (制药和生物技术公司, 合同研究组织)

    • What is the historic period, base year, and forecast period taken for Asia Pacific Pharmacokinetics Services Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Pharmacokinetics Services Market report:

  • Historic Period : 2021-2022
  • Base Year : 2023
  • Forecast Period : 2024-2031
    • Who are the major players in Asia Pacific Pharmacokinetics Services Market?

    The Asia Pacific Pharmacokinetics Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Allucent
  • Certara Inc.
  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • PACIFIC BIOLABS
  • Parexel International Corp
  • SGS SA
  • Shanghai Medicilon Inc.
  • Thermo Fisher Scientific Inc.
    • Who should buy this report?

    The Asia Pacific Pharmacokinetics Services Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Pharmacokinetics Services Market value chain can benefit from the information contained in a comprehensive market report.

    asia-pacific-pharmacokinetics-services-market